Strides Arcolab has received ANDA approval for its skin drug Imiquimod Crème by United States Food & Drug Administration (USFDA). This is first product approval from Beltapharm, the company’s UFDA approved semi solids facility in Milan, Italy. The product will be marketed directly by Strides in the US market.
Imiquimod Crème is a topical skin crème indicated for the treatment of certain types of actinic keratoses on the face or scalp, and the external genital and perianal warts in patients, aged 12 years or older. According to IMS data, the US market for generic Imiquimod Crème is approximately $140 million.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
